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Predicting metabolictransformation is one of major chal-
lenges in drug discovery [1]. Sulfotransferase 1A1
(SULT1A1), one of phase II metabolismenzymes, is the
major SULT in adult liver catalysis [2]. It metabolizes
many endogenous compounds and is relevant in carci-
nogenesis due to its ability to modify diverse promuta-
gen and procarcinogen xenobiotics [3].
In order to make a discriminative model that classifies
group of SULT1A1 binders into substrates and inhibi-
tors, a combination of structure, ligand-based, and dock-
ing based pharmacophores have been generated and
validated by Ligandscout [4].
On one hand, structure-based pharmacophores have
been derived from PDB files of good binders (substrates
and inhibitors). On the other hand, ligand-based interac-
tion maps have been conducted from some drug classes
that show different substrate/inhibitor activity towards
SULT1A1.Finally, highly active substrates and inhibitors
have been docked into the enzyme using GOLD [5], and
subsequently molecular interaction fields have been devel-
oped for the most plausible poses.
As a retrospective validation, all pharmacophores
simultaneously have been used to screen more than 100
SULT1A1 binders covering several activity classes and
different chemical scaffolds. The model showed good dis-
criminative power to differentiate between inhibitors,
substrates and mixed substrates/inhibitors.
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